Scarica l'app Stockscreener
16.03
1.65%
0.26
Dopo l'orario di chiusura:
15.97
-0.06
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.77
Aprire:
$15.92
Volume 24 ore:
87,086
Relative Volume:
1.26
Capitalizzazione di mercato:
$336.13M
Reddito:
$217.21M
Utile/perdita netta:
$-33.72M
Rapporto P/E:
-9.8926
EPS:
-1.6204
Flusso di cassa netto:
$25.63M
1 W Prestazione:
+7.58%
1M Prestazione:
+14.01%
6M Prestazione:
+15.91%
1 anno Prestazione:
+20.26%
Intervallo 1D:
$15.55
$16.30
Intervallo di 1 settimana:
$14.81
$16.30
Portata 52W:
$12.30
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Nome
Amarin Corp Adr
Settore
Industria
Telefono
353 1 6699 020
Indirizzo
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
16.03 | 336.13M | 217.21M | -33.72M | 25.63M | -1.6204 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-10-25 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-05-05 | Iniziato | Northland Capital | Outperform |
| 2020-03-31 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-31 | Aggiornamento | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-02 | Iniziato | Cowen | Outperform |
| 2020-02-18 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-01-06 | Iniziato | JP Morgan | Neutral |
| 2019-12-16 | Downgrade | Stifel | Buy → Hold |
| 2019-11-20 | Iniziato | Oppenheimer | Underperform |
| 2019-11-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-11-15 | Reiterato | SVB Leerink | Outperform |
| 2019-10-31 | Iniziato | Aegis Capital | Buy |
| 2019-10-15 | Iniziato | Goldman | Neutral |
| 2019-08-14 | Iniziato | SVB Leerink | Outperform |
| 2019-07-09 | Reiterato | Jefferies | Buy |
| 2019-06-17 | Iniziato | ROTH Capital | Buy |
| 2019-03-22 | Iniziato | Stifel | Buy |
Mostra tutto
Amarin Corp Adr Borsa (AMRN) Ultime notizie
Net income before discontinued operations of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Price to book ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Free cash flow per share of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Diluted earnings per share (diluted EPS) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – DUS:EH3 - TradingView
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma - Benzinga
AMRN Technical Analysis | Trend, Signals & Chart Patterns | AMARIN CORP PLC -ADR (NASDAQ:AMRN) - ChartMill
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Amarin shareholders reject key proposals at annual meeting, limit equity grants - Investing.com
Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools - Stock Titan
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales - TradingView
Amarin (AMRN) Loss Trend Of 24.2% Annually Tests Turnaround Narratives Heading Into Q1 - Sahm
Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs - ChartMill
Amarin Corp PLC (FRA:EH3) Stock Price, Trades & News - GuruFocus
Amarin Corporation Plc Sponsored ADR Trade Ideas — FWB:EH3 - TradingView
Will Amarin (AMRN) Stock Go Higher | Price at $14.77, Up 0.20%Hot Stock Picks - The Legal Advocate
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz
Amarin Corporation Plc Sponsored ADR Trade Ideas — SWB:EH3 - TradingView
Amarin (NASDAQ: AMRN) details VASCEPA reach, Recordati deal and $70M savings - Stock Titan
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss - Finviz
Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 - ChartMill
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Finviz
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - Finviz
China Universal Asset Management Co. Ltd. Sells 76,302 Shares of Amarin Corporation PLC $AMRN - Defense World
Net current asset value per share of Amarin Corporation Plc Sponsored ADR – MUN:EH3 - TradingView — Track All Markets
Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight - Law360
Leerink Partners raises Amarin stock price target to $12 on strong Q3 - Investing.com
FDA updates fenofibrate labels to reflect lack of cardiovascular benefit - Investing.com
Amarin stock rises after ESC Congress data on VASCEPA mechanism - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect - Finviz
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Finviz
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Which stocks are gapping on Tuesday? - ChartMill
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Finviz
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease - Finviz
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Finviz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines - Finviz
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Finviz
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies - Finviz
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigat - GuruFocus
Global X Aging Population ETF Holdings - Quiver Quantitative
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Amarin Corp Adr Azioni (AMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):